Dr Claudio Cerchione gives his thoughts on key studies in multiple myeloma from EHA 2024.
He talks about the consolidated data from the GRIFFIN and EMERALD studies. In the refractory setting, Dr Cerchione mentions the DREAMM-7 and DREAMM-8 studies.
He also discusses studies investigating new treatment methods, cellular therapies and chemotherapy interpretation.
Dr Cerchione concludes by talking about what is next in the treatment of multiple myeloma in the future.